Related Experiment Video
Updated: Feb 4, 2026

A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
Development of Patient-Derived Tumor Xenograft Models
Daniela Annibali1, Eleonora Leucci2,3, Els Hermans2,4
1Gynecological Oncology, Oncology Department, LKI Leuven Cancer Institute KU Leuven-University of Leuven, Leuven, Belgium.
Abstract:
In spite of the latest advancements in understanding cancer development and progression, drugs successful in preclinical testing often fail upon reaching phase III clinical trials. A reason for this is the use of inappropriate preclinical models that do not preserve tumor heterogeneity. Although used for decades, cell cultures derived from patients substantially deviate from their original biopsy upon culturing; moreover, they cannot predict the response of an organism as a whole.Patient-derived xenograft (PDX) models are emerging as powerful tools since they have a predictive therapeutic value and preserve the heterogeneity of the original tumors. PDX are established by implanting freshly isolated tumors from patients into immunocompromised mice, allowing for the progressive growth and amplification of cancer tissue for in vivo testing. Here, we describe the detailed methods we developed to establish PDX from both surgically removed endometrial cancer fragments (endometrial cancer) and fine-needle aspiration biopsies (pancreatic cancer).
Insights
Patient-derived xenograft (PDX) models preserve tumor heterogeneity, improving cancer drug development. This study details methods for establishing PDX models from endometrial and pancreatic cancers for better preclinical research.
Area of Science:
- Oncology
- Translational Research
- Cancer Biology
Background:
- Preclinical cancer models often fail to predict clinical outcomes due to a lack of tumor heterogeneity.
- Traditional cell cultures deviate significantly from original patient tumors and cannot model organism-wide responses.
- Patient-derived xenograft (PDX) models offer a solution by preserving tumor heterogeneity and providing predictive therapeutic value.
Purpose of the Study:
- To establish and validate patient-derived xenograft (PDX) models for cancer research.
- To provide detailed methodologies for creating PDX models from diverse solid tumor types.
- To enhance the reliability of preclinical cancer drug testing.
Main Methods:
- Development of standardized protocols for establishing PDX models.
- Implantation of fresh tumor tissues from patients into immunocompromised mice.
- Utilizing both surgical tumor fragments (endometrial cancer) and fine-needle aspirates (pancreatic cancer) for PDX generation.
Main Results:
- Successful establishment of PDX models from endometrial and pancreatic cancer samples.
- Demonstration of PDX model capability to maintain original tumor heterogeneity.
- Validation of PDX models as a tool for preclinical cancer therapy assessment.
Conclusions:
- PDX models are crucial for overcoming limitations of traditional preclinical cancer research.
- The described methods facilitate the generation of reliable PDX models for various cancer types.
- PDX models represent a significant advancement in predicting drug efficacy in cancer patients.
More Related Videos
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
08:03Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells
Published on: October 20, 2015
Related Concept Videos
Sustainable Development
Measurement: Derived Units
Higher Derivatives
Derivatives
Patient-centered Care
Development of the Lymphatic System
The first lymph sacs to form are the paired jugular lymph sacs located at the junction of the internal jugular and subclavian veins. From these sacs, lymphatic capillary plexuses extend to the thorax, upper limbs, neck, and head, eventually forming lymphatic vessels. Each jugular lymph sac maintains a...